Literature DB >> 2157679

Establishment of immortalized primate epithelial cells with sub-genomic EBV DNA.

L Karran1, C G Teo, D King, M M Hitt, Y N Gao, N Wedderburn, B E Griffin.   

Abstract

The genetic information in a sub-fragment of EBV DNA, designated p31 (containing less than a quarter of the viral genome and derived from a recombinant DNA cosmid library) allows epithelial cells from primary monkey and human kidney cultures to escape senescence under standard tissue culture conditions. A number of epithelial cell lines, designated M1/31, 483/31, 199/31 and HK/31, have been established and characterized following transfection of primary cells with p31 DNA. They share many properties, although morphologically they are not all identical. The cultures are immortalized but not fully transformed or tumorigenic. They appear to be phenotypically stable, although DNA hybridization studies indicate that genotypic alterations, including amplification, occur subsequent to transfection with p31 DNA and the establishment of a continuously proliferating epithelium. All cell lines consistently express high levels of cytokeratin 18 and varying amounts of cytokeratin 7, demonstrating their epithelial origin. From a single marmoset kidney (designated 199) a series of related immortalized cells, with subtle phenotypic differences, have been generated by p31 or sub-fragments of it. Although hallmarks of a "hit-and-run" mechanism are apparent in all of our studies, 2 different techniques (in situ hybridization or selection for cell survival in semi-solid media, followed by nucleic acid hybridization) show that, in late-passaged cultures, a small proportion of the cells still contain some viral DNA. The studies focus on genetic information within the BamHI A and I regions as being relevant to immortalization. The role of the EBV DNA fragment in the genesis of epithelial cell lines is considered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157679     DOI: 10.1002/ijc.2910450432

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Meeting report. Report of meeting of Section of Clinical Immunology and Allergy, 11 March 1991.

Authors: 
Journal:  J R Soc Med       Date:  1992-02       Impact factor: 5.344

2.  Differential expression of Epstein Barr viral transcripts for two proteins (TP1 and LMP) in lymphocyte and epithelial cells.

Authors:  P R Smith; B E Griffin
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

3.  Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors.

Authors:  P R Smith; Y Gao; L Karran; M D Jones; D Snudden; B E Griffin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

4.  E-cadherin and beta-catenin expression in Epstein-Barr virus-associated gastric carcinoma and their prognostic significance.

Authors:  Chihaya Koriyama; Suminori Akiba; Tetsuhiko Itoh; Kazunobu Sueyoshi; Yoshie Minakami; Alejandro Corvalan; Suguru Yonezawa; Yoshito Eizuru
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

Review 5.  BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator.

Authors:  Eveline K Hoebe; Tessa Y S Le Large; Astrid E Greijer; Jaap M Middeldorp
Journal:  Rev Med Virol       Date:  2013-08-31       Impact factor: 6.989

6.  A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

Authors:  Riccardo Turrini; Anna Merlo; Debora Martorelli; Damiana Antonia Faè; Roberta Sommaggio; Isabella Monia Montagner; Vito Barbieri; Oriano Marin; Paola Zanovello; Riccardo Dolcetti; Antonio Rosato
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

7.  Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger?

Authors:  S A Xue; I A Lampert; J S Haldane; J E Bridger; B E Griffin
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.